Vertex says combo of Roche drugs, telaprevir shows promise in study

04/27/2009 | Bloomberg

Vertex Pharmaceuticals announced that the combination of its hepatitis C drug telaprevir with Roche Holding's Pegasys and Copegus eradicated signs of the virus and elicited sustained response in 52% of patients, compared with 14% of those who received Roche's medicines alone. The yearlong study observed 453 patients who either relapsed after or failed to respond to previous hepatitis C therapies.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA